[Experimental psychological study of the effect of a hexobendine-etamivan-etofylline combination].
Instenon forte, a combination of hexobendine, etamivan and etofylline for treatment of cerebral vascular insufficiency, was tested in an experimental psychological study. Effects on performance, especially on functions related to driving, were investigated. The experimental group consisted of 15 male and 9 female, the control group of 15 male and 8 female students, aged between 17 and 25 years. All subjects were tested with the same series of psychological tests before and after long-term medication. The male subjects showed moderate increase of concentration performance and short-term memory under Instenon in various tests. Taking in complex traffic situations at a glance was significantly enhanced in the male experimental group, whereas reactive behavior under stress showed some impairment. In the female experimental group an increase of focal attention and an improvement of reactive behavior under stress was found, taking in complex traffic situations at a glance was impaired. The results of this study indicate that neither in female nor in male subjects a consistent positive or negative effect of Instenon on functions related to driving could be determined. Driving fitness in general is not influenced by Instenon in the dosage applied in young healthy volunteers.
D000293:Adolescent; D000328:Adult; D001288:Attention / Q000187:drug effects; D001549:Benzamides / Q000494:pharmacology*; D001565:Benzoates / Q000494:pharmacology*; D004338:Drug Combinations; D005260:Female; D006592:Hexobendine / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects; D009048:Motor Skills / Q000187:drug effects; D013647:Task Performance and Analysis; D013806:Theophylline / Q000031:analogs & derivatives* / Q000494:pharmacology; D013997:Time Factors
D001549:Benzamides; D001565:Benzoates; D004338:Drug Combinations; D006592:Hexobendine; D013806:Theophylline
Experimentalpsychologische Untersuchung der Wirkung einer Hexobendin-Etamivan-Etofyllin-Kombination